Reproductive-technology medical device · EVEA™

Decentralizing embryo culture.

The EVEA™ platform combines specialized culture environments with proprietary operational protocols, enabling healthcare networks to activate intravaginal culture as a streamlined, clinic-adjacent service-line. For established fertility operators, it frees finite embryology-lab capacity. For new entrants, it removes the cleanroom barrier entirely.

Request a briefing → Explore EVEA™ ↗

Image for illustrative purposes only. EVEA™ is an investigational device under development; the final product may differ.

The Constraint

Fertility capacity is limited by a fixed resource: the embryology laboratory.

Every conventional IVF cycle consumes scarce embryology-lab hours, embryologist time and incubator capacity — capping how many cycles a centre can run, and confining fertility services to high-infrastructure urban hospitals. The binding constraint is the lab, not patient demand.

1 in 6

people affected by infertility worldwide — a WHO-recognised disease.

$1M+

typical capital barrier to build a conventional embryology cleanroom.

~59%

reduction in embryology-lab hours per cycle with EVEA™ (Eve model).

35+ yrs

of published intravaginal-culture clinical history.

Sources: WHO; market benchmarks (BDA Partners, SART). Operational figure reflects Eve cycle modelling.

Where we focus

Built for Asia-Pacific — to bring advanced fertility care to the secondary cities and underserved regions that conventional embryology infrastructure does not reach.

EVEA™ decentralizes the culture phase, so a hospital can deliver assisted reproduction without the cleanroom, the incubator bank, or the specialist lab a major urban centre requires.